[
  {
    "ts": null,
    "headline": "Playing The Odds Of Anavex Alzheimer's Drug Approval",
    "summary": "Anavex's promising Alzheimer's drug, Blarcamesine, could provide hope with its potential to slow cognitive decline, pending EMA approval. Read more here.",
    "url": "https://finnhub.io/api/news?id=d7f2f2cd0018cd4b7b4806031418618487a9642dc9c251b62d875f44f017c784",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736680912,
      "headline": "Playing The Odds Of Anavex Alzheimer's Drug Approval",
      "id": 132382416,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1279693289/image_1279693289.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Anavex's promising Alzheimer's drug, Blarcamesine, could provide hope with its potential to slow cognitive decline, pending EMA approval. Read more here.",
      "url": "https://finnhub.io/api/news?id=d7f2f2cd0018cd4b7b4806031418618487a9642dc9c251b62d875f44f017c784"
    }
  }
]